Skip to content

The Effect of Pomegranate Peel, German Chamomile or Their Combination on Gingivitis

The Effect of Mouthwashes Containing Pomegranate Peel, German Chamomile or Their Combination in the Treatment of Gingivitis

Status
UNKNOWN
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05951647
Enrollment
60
Registered
2023-07-19
Start date
2023-07-11
Completion date
2023-11-30
Last updated
2023-07-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gingivitis

Keywords

Pomegranate peel, German chamomile, TNF-α, IL-1β

Brief summary

The aim of this study is to compare clinically and biochemically the effect of herbal mouthwashes containing German chamomile and pomegranate peel extracts individually and as a mixture to chlorohexidine mouthwash in the treatment of gingivitis. The response will be assessed clinically and by suitable biochemical parameters.

Detailed description

1. Ethical committee approval has been obtained from Ethics committee of Faculty of Medicine and Faculty of Dentistry, Alexandria University 2. All participants should agree to take part in this clinical study and will provide informed consent. 3. Sixty plaque induced gingivitis patients ,will be recruited from Faculty of Dentistry, Alexandria University. 4. The 60 participants will be randomly assigned into 5 groups. Group 1: Patients will be managed by scaling. Group 2: Patients will be managed by scaling and will use 0.12%% chlorohexidine mouthwash in a dose of 15 ml twice daily. Group 3: Patients will be managed by scaling and will use 5% chamomile extract mouthwash in a dose of 15 ml twice daily. Group 4: Patients will be managed by scaling and will use 5% pomegranate peel extract mouth wash in a dose of 15 ml twice daily. Group 5: Patients will be managed by scaling and will use a combination of 5% chamomile extract and pomegranate peel extract mouthwash in a dose of 15 ml twice daily. 5. All patients will be submitted to: * Full patient history and clinical examination. * Gingival index will be measured * Saliva samples will be obtained in order to conduct ELISA for the selected biomarkers. * Different mouthwashes will be provided to patients. 6. Statistical tests appropriate to the study design will be conducted to evaluate the significance of the results. 7. Results, conclusion, discussion and recommendations will be given.

Interventions

DRUGChamomile extract mouthwash

5% chamomile extract mouthwash in a dose of 15 ml twice daily.

DRUGPomegranate peel extract mouth wash

5% pomegranate peel extract mouth wash in a dose of 15 ml twice daily.

DRUGCombination of 5% chamomile extract and pomegranate peel extract mouthwash

Use a combination of 5% chamomile extract and pomegranate peel extract mouthwash in a dose of 15 ml twice daily.

PROCEDUREScaling

Patients will be managed by scaling

DRUGScaling and Chlorohexidine mouthwash

scaling and will use 0.12%% chlorohexidine mouthwash in a dose of 15 ml twice daily.

Sponsors

Alexandria University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Caregiver)

Intervention model description

Double-blinded, parallel, randomized clinical trial

Eligibility

Sex/Gender
ALL
Age
25 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Age: 25-50 * Patients with plaque induced gingivitis.

Exclusion criteria

* Patients with systemic diseases (diabetes, leukemia, anemia) * Smokers * Pregnant females * Patients receiving orthodontic treatment

Design outcomes

Primary

MeasureTime frameDescription
Clinical assessment for the gingival index (GI)15 daysThe gingival index will measured before treatment, 7 days, and 15 days after treatment respectively.

Secondary

MeasureTime frameDescription
Measurement of TNF-α saliva level15 daysTNF-α saliva level will be measured before treatment, 7 days, and 15 days after treatment respectively.
Measurement of IL1β saliva level15 daysIL1β saliva level will be measured before treatment, 7 days, and 15 days after treatment respectively.

Countries

Egypt

Contacts

Primary ContactNoha A Hamdy, PhD
noha.alaaeldine@alexu.edu.eg1005182151
Backup ContactMarwa A Alashwah, PharmD
gs-marwa.alashwah@alexu.edu.eg1223467205

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026